AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34966017
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural steroid injection (CESI)
Trial: 35322972
Drug: Transforaminal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal epidural steroid injection (TFESI)
Trial: 32594305
Drug: Rectal omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal omeprazole (1 mg/kg)
Trial: 32594305
Drug: Oral omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral omeprazole (1 mg/kg)
Trial: 32594305
Drug: Rectal omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal omeprazole
Trial: 32870520
Drug: Antidepressants prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants prescription
Trial: 32198596
Drug: MSC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC therapy (Men‐MSCs)
Trial: 34777570
Drug: Traditional paralysis
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional paralysis treatment
Trial: 32444033
Drug: Lavender herbal
RxNorm normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lavender herbal tea (2 g teabag, 2 times daily for 2 weeks)
Trial: 32579066
Drug: Pyrazole based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrazole based sulfonamides; specific compounds include NMT106, NMT157, NMT187, NMT236; dosage and duration not specified.
Trial: 34408049
Drug: No antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiviral treatment (Control)
Trial: 33801767
Drug: High-flavanol cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavanol cocoa (150 mg)
Trial: 33801767
Drug: Low-flavanol cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flavanol cocoa (<4 mg (‐)‐epicatechin)
Trial: 32163799
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml of grape juice
Trial: 32163799
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g maltodextrin
Trial: 32163799
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no sugar administration)
Trial: 34049672
Drug: 1 to
RxNorm normalized name: Cep-11981 tosylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 3 months of dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy
Trial: 32122921
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cytarabine
Trial: 32122921
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose cytarabine
Trial: 36208303
Drug: Mindfulness-Based Intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Intervention (MB-SI) and Treatment as Usual (TAU)
Trial: 34044838
Drug: Hypnosis group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis group (standardized hypnotic message)
Trial: 32167593
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for former smokers
Trial: 32167593
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for current smokers
Trial: 32167593
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for former smokers with ≤20 pack-years
Trial: 32167593
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for all patients
Trial: 32482611
Drug: 5% aluminium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% aluminium zirconium tetrachlorohydrate antiperspirant solution (AZCH)
Trial: 32197030
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (GA) (group G)
Trial: 37183134
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy in stoma patients
Trial: 32194443
Drug: Cariprazine (1.5-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine (1.5-6 mg)
Trial: 33142503
Drug: L-DNJ (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DNJ (0.05 mg/g)
Trial: 33142503
Drug: M-DNJ (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-DNJ (0.1 mg/g)
Trial: 33142503
Drug: H-DNJ (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-DNJ (0.15 mg/g)
Trial: 36433591
Drug: Carbetocin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin (100 μg intramuscularly)
Trial: 35245895
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (KT, KT-placebo, No-treatment control)
Trial: 35613725
Drug: Eldecalcitol 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eldecalcitol 0.75 μg per day (n=630)
Trial: 34988058
Drug: Digital intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital intervention for medication adherence
Trial: 34988058
Drug: Tailored intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tailored intervention content and reporting on medication taking
Trial: 33278330
Drug: Single ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose (SAD) of vixotrigine
Trial: 33278330
Drug: Multiple ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending dose (MAD) of vixotrigine (450 mg twice daily)
Trial: 34684368
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg·kg−1)
Trial: 32516494
Drug: Sequential text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential text descriptions
Trial: 2012036615
Drug: Olmesartan, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan, 40 mg daily
Trial: 32639293
Drug: Intranasal oxytocin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin, n = 6
Trial: 33405291
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (triggered by hemoglobin ≤8 g/dL)
Trial: 33405291
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (triggered by hemoglobin ≤10 g/dL)
Trial: 34659110
Drug: Dulening metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulening metformin SR tablets (n=446)
Trial: 34659110
Drug: Glucophage metformin
RxNorm normalized name: metformin Oral Tablet [Glucophage]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucophage metformin tablets (n=440)
Trial: 34708917
Drug: Difelikefalin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difelikefalin (5 and 15 mcg/kg)
Trial: 33388858
Drug: Curcuminoids 500
RxNorm normalized name: METHYLCOBALAMIN 1 mg / LEVOMEFOLIC ACID 1 mg / CURCUMINOIDS 500 mg ORAL CAPSULE [Rheumate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids 500 mg/day
Trial: 33388858
Drug: Curcuminoids 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids 1000 mg/day
Trial: 34415561
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 25 mg Omecamtiv mecarbil (OM)
Trial: 34415561
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 50 mg Omecamtiv mecarbil (OM)
Trial: 34415561
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of 25 mg Omecamtiv mecarbil (OM)
Trial: 34415561
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of 37.5 mg or 50 mg Omecamtiv mecarbil (OM)
Trial: 39166327
Drug: Colchicine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.5 mg once daily)
Trial: 35065057
Drug: Nivolumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab monotherapy (240 mg every 2 weeks for up to three doses before surgery, then 480 mg every 4 weeks for 2 years)
Trial: 35065057
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (240 mg nivolumab every 2 weeks plus 1 mg/kg ipilimumab concurrently with the first preoperative dose, then 480 mg nivolumab every 4 weeks for 2 years plus 1 mg/kg ipilimumab every 6 weeks for up to four cycles)
Trial: 32827517
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ropinirole
Trial: 34521264
Drug: 100,000 IUs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100,000 IUs of ergocalciferol monthly after bariatric surgery
Trial: 34521264
Drug: Standard level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard level vitamin D supplement after bariatric surgery
Trial: 34192426
Drug: NVX-CoV2373 vaccine
RxNorm normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVX-CoV2373 vaccine (5-μg doses, 2 doses administered 21 days apart)
Trial: 34192426
Drug: NVX-CoV2373 vaccine
RxNorm normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVX-CoV2373 vaccine and placebo
Trial: 32919280
Drug: CER-001 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CER-001 (8 mg/kg, intravenous infusions, 9 weekly infusions followed by infusions every two weeks)
Trial: 32414130
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels < 30 ng/mL in AS patients
Trial: 32414130
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels < 20 ng/mL in AS patients
Trial: 32414130
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels < 10 ng/mL in AS patients
Trial: 32414130
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels < 30 ng/mL in male AS patients
Trial: 32414130
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels < 20 ng/mL in male AS patients
Trial: 32414130
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels < 10 ng/mL in male AS patients
Trial: 32374239
Drug: Systemic+short infusion
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic+short infusion TXA
Trial: 32374239
Drug: Systemic+long infusion
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic+long infusion TXA
Trial: 32374239
Drug: Systemic+oral TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic+oral TXA
Trial: 34582653
Drug: Lisinopril and
RxNorm normalized name: lisinopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril and Bisoprolol
Trial: 32312606
Drug: Classification-specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classification-specific treatment (exercise to control or prevent lumbopelvic motion during lower-extremity movement)
Trial: 33740977
Drug: Opioid analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid analgesia alone (standard treatment)
Trial: 33740977
Drug: Multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesia (Pregabalin, Acetaminophen, Naproxen, and opioids if required)
Trial: 33879005
Drug: Treatment-resistant depression
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-resistant depression (TRD)
Trial: 33834177
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (isoniazid for all 14 days, n=18)
Trial: 35576286
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural anaesthesia with 12 ml of 0.25% bupivacaine and 1% lignocaine plain (Group T)
Trial: 33940347
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg every 3 weeks or 400 mg every 6 weeks by intravenous infusion)
Trial: 33940347
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC: FOLFOX6/FOLFIRI alone or in combination with bevacizumab/cetuximab)
Trial: 34082792
Drug: Ayurveda interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ayurveda interventions including Agastya Haritaki 6g and Ashwagandha tablet 500mg twice daily orally after meals with warm water and two sessions of yoga (morning 30 minutes and evening 15 minutes) daily for 90 days.
Trial: 36127739
Drug: Inhaled aviptadil
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled aviptadil (67 μg, three times a day for 10 days)
Trial: 36425919
Drug: Pre-emptive ultrasound-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive ultrasound-guided single-shot lateral sciatic nerve block with 20 ml of 0.75% ropivacaine
Trial: 32763109
Drug: Bevacizumab 15
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg, paclitaxel 175 mg/m(2), and carboplatin AUC 5; median bevacizumab duration was 6.7 months; 57% received maintenance bevacizumab.
Trial: 32150521
Drug: Restrictive 72-hour
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive 72-hour short-term antibiotic strategy
Trial: 32150521
Drug: Standard antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotic usage
Trial: 32150521
Drug: Restrictive antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive antibiotic strategy
Trial: 35575766
Drug: Propofol‐remifentanil total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol‐remifentanil total intravenous anesthesia alone
Trial: 35587574
Drug: ArtemiC oral
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Extended Release Oral Tablet [Xartemis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ArtemiC oral spray, twice daily on Days 1 and 2, beside standard care
Trial: 35587574
Drug: Placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral spray, twice daily on Days 1 and 2, beside standard care
Trial: 34028012
Drug: Transnasal Humidified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE), FIO2 1.0, 70 L min−1 during apnoea
Trial: 32503652
Drug: Dill powder
RxNorm normalized name: Dill
DrugBank: Dill (DB10673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dill powder supplementation (3 g/day)
Trial: 36130734
Drug: Opioid antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Opioid antagonists
Trial: 34049922
Drug: Exenatide 2
RxNorm normalized name: exenatide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 2 mg weekly
Trial: 33446039
Drug: 3D‐MOT training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D‐MOT training (twice per week for 12 weeks)
Trial: 35949922
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg in 0.4 mL), four injections every 3 months
Trial: 35949922
Drug: Saline (placebo),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (placebo), four injections every 3 months
Trial: 39478521
Drug: Low-dose dobutamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dobutamine infusion
Trial: 33570701
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 50,000 IU PO weekly for 12 weeks
Trial: 33270145
Drug: Juul EU
RxNorm normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juul EU (20 mg/ml)
Trial: 33270145
Drug: Juul US
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juul US (59 mg/ml)
Trial: 38278871
Drug: Ivosidenib 500
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivosidenib 500 mg once daily
Trial: 34050857
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy for Suicide Prevention + treatment as usual (CTSP + TAU) (N=75)
Trial: 34050857
Drug: treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment as usual (TAU) alone (N=75)
Trial: 34968972
Drug: Sequential Multiple-Assignment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Multiple-Assignment Randomized Trial (SMART)
Trial: 33986878
Drug: Booklet +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booklet + Oral Presentation
Trial: 33986878
Drug: Booklet +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booklet + Oral Presentation + Clinical Teaching
Trial: 33021606
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (15 mg twice daily for 2 weeks, followed by clarithromycin [500 mg daily] for 12 weeks)
Trial: 33021606
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (15 mg twice daily for 2 weeks, followed by placebo for 12 weeks)
Trial: 32730905
Drug: Apixaban (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (2.5 mg twice daily) plus aspirin (100 mg once daily) for 12 months
Trial: 32730905
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg daily) for at least 3 months on a background of aspirin (100 mg once daily) for 12 months
Trial: 34212177
Drug: Provider-targeted intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider-targeted intervention including education on appropriate RTD prescribing and monthly peer comparison feedback.
Trial: 32541462
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal patch (BTP) 10 mg for 14 days
Trial: 32541462
Drug: Conventional analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional analgesic regimen (IV paracetamol 1 mg every 8 hours alternating with parenteral tramadol 50 mg every 8 hours for the first 2 postoperative days, followed by oral administration of the same drug until the end of 2 weeks)
Trial: 35305278
Drug: HEAT (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEAT (5 × 50 min weekly heat suit training sessions)
Trial: 35238765
Drug: MIV-711 100
RxNorm normalized name: MIV-711
DrugBank: MIV-711 (DB15599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIV-711 100 mg
Trial: 35238765
Drug: MIV-711 200
RxNorm normalized name: MIV-711
DrugBank: MIV-711 (DB15599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIV-711 200 mg
Trial: 32434362
Drug: Plum blossom
RxNorm normalized name: OCTISALATE 4.7 g in 100 g / ZINC OXIDE 15 g in 100 g TOPICAL LIPSTICK [TATCHA THE KISSU LIP TINT SPF 25 PLUM BLOSSOM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plum blossom needle acupuncture with qi-invigorating superficies-consolidating therapy
Trial: 34392492
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide (Gr.A)
Trial: 33481251
Drug: Acute intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute intravenous glucose-induced hyperglycaemia
Trial: 34751757
Drug: Early surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early surgical treatment within 24 hours after admission
Trial: 34751757
Drug: Delayed surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed surgical treatment after at least 2 weeks of conservative treatment
Trial: 33038271
Drug: 0.8 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg alcohol dose
Trial: 34290294
Drug: FLNA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLNA and CLU combination
Trial: 34290294
Drug: FLNA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLNA and CLU combination (with hepatic fibrosis and non-alcoholic fatty liver as control)
Trial: 35502002
Drug: Cognitive-reminiscence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-reminiscence therapy (CRT)
Trial: 34590570
Drug: Senling Baizhu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senling Baizhu san (SLBZS) 100 mL, twice a day, for 12 weeks